Clinical Trial Update: GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating GS-5734 (remdesivir) antiviral activity, longer-term clearance, and safety in male Ebola survivors with persistent Ebola virus i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola

Drugs mentioned

• GS-5734 (remdesivir)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Ebola | Phase 2 | Status: COMPLETED | Results posted: 2022-02-15